Affiliation:
1. Merck Research Laboratories, Rahway, New Jersey 07065.
Abstract
The lipopeptide antifungal agents, echinocandins, papulacandins, and pneumocandins, kill Candida albicans by inhibiting glucan synthesis. For this fungus, there is a good correlation of in vitro enzyme inhibition with in vitro assays of MICs. Semisynthetic lipopeptides such as cilofungin, LY303366, L-693,989, and L-733,560 have activity in vivo against Aspergillus infections but appear to be inactive in broth dilution in vitro tests (MICs, > 128 micrograms/ml). To understand how compounds which lack activity in vitro can have good in vivo activity, we monitored the effect of pneumocandins on the morphology of Aspergillus fumigatus and A, flavus strains by light microscopy and electron microscopy and related the changes in growth to inhibition of glucan synthesis. Pneumocandin B0 caused profound changes in hyphal growth; light micrographs showed abnormally swollen germ tubes, highly branched hyphal tips, and many cells with distended balloon shapes. Aspergillus electron micrographs confirmed that lipopeptides produce changes in cell walls; drug-treated germlings showed very stubby growth with thick walls and a conspicuous dark outer layer which was much thicker in the subapical regions. The rest of the hyphal tip ultrastructure was unaffected by the drug, indicating considerable specificity for the primary target. The drug-induced growth alteration produced very compact clumps in broth dilution wells, making it possible to score the morphological effect macroscopically. The morphological changes could be assayed quantitatively by using conventional broth microdilution susceptibility assay conditions. We defined the endpoint as the lowest concentration required to produce the morphological effect and called it the minimum effective concentration to distinguish it from the no-growth endpoints used in MIC determinations. The minimum effective concentration assay was related to inhibition of glucan synthase activity in vitro and may provide a starting point for development of susceptibility testing methods for lipopeptides.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference52 articles.
1. Abruzzo G. K. A. M. Flattery C. J. Gill J. G. Smith H. Kropp and K. F. Bartizal. 1993. Evaluation of water soluble lipopeptides L-733 560 L-705 589 and L-731 373 in a mouse model of disseminated aspergillosis abstr. 355. Program Abstr. 33rd Intersci. Conf. Antimicrob. Agents Chemother. New Orleans La.
2. Pneumocandins from Zalerion arboricola. IV. Biological evaluation of natural and semisynthetic pneumocandins for activity against Pneumocystis carinii and Candida species;Balkovec J. M.;J. Antibiot.,1992
3. In vitro antifungal activities and in vivo efficacies of 1,3-13-D-glucan synthesis inhibitors L-671,329, L-646,991, tetrahydroechinocandin B, and L-687,781, a papulacandin;Bartizal K.;Antimicrob. Agents Chemother.,1992
4. Cell-wall chemistry, morphogenesis, and taxonomy of fungi. Annu;Bartnicki-Garcia S.;Rev. Microbiol.,1968
5. Correlation of cilofungin in vivo efficacy with its activity against Aspergillus fimigatus (1,3)-p-D-glucan synthase;Beaulieu D.;FEMS Microbiol. Lett.,1993
Cited by
307 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献